*Estimates of patients treated reflect global data since launch (Apr 2014-Aug 2022; US=approximately 60% of
data). Calculations based on observed drug utilization
parameters and number of units distributed. Utilization patterns change over time to best represent current
FDA, U.S. Food and Drug Administration; PsA, psoriatic arthritis; TB, tuberculosis.
References: 1. Otezla [package insert]. Thousand Oaks, CA: Amgen Inc. 2. Data
on file, Amgen Inc. 3. Otezla® (apremilast) FDA approval letter. March 21, 2014.
Support services are available for Otezla patients—don’t wait to get your patients started
WITH ONE SIMPLE ENROLLMENT, COMMERCIALLY INSURED PATIENTS CAN NOW ACCESS BOTH THE OTEZLA $0 CO-PAY CARD * AND BRIDGE PROGRAM †
While pursuing coverage, commercially insured patients can enroll in the combined Otezla Co-Pay Card * and Bridge Program† to start and stay on Otezla as prescribed for as little as $0.
*The Otezla Co-Pay Card is for eligible commercially insured patients. Terms, conditions, and program maximums apply. Other restrictions may apply. Click here for full Terms and Conditions. This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program. Not valid where prohibited by law. Patients who are not eligible can call 1-844-4OTEZLA (1-844-468-3952) to discuss further financial support opportunities. †If the patient’s health plan requires a prior authorization, or if patient experiences a delay in obtaining approval for Otezla, patients can qualify for the Bridge to Commercial Coverage Offer and receive Otezla free for up to 12 months while pursuing approval from their health plans. No purchase necessary. Click here for full Terms and Conditions.
3 SIMPLE WAYS FOR PATIENTS TO ENROLL IN THE CO-PAY PROGRAM:
ENCOURAGE COMMERCIALLY INSURED PATIENTS TO ENROLL IN
THE COMBINED $0 CO-PAY CARD AND BRIDGE PROGRAM FOR OTEZLA BEFORE LEAVING THE OFFICE
WE ARE COMMITTED TO HELPING YOUR PATIENTS ACCESS OTEZLA AT LOW COST
For your uninsured or underinsured patients, Otezla SupportPlus® can put them in touch with the Amgen Safety Net Foundation, a nonprofit patient support program sponsored by Amgen that helps qualifying patients access Otezla and other Amgen medicines at no cost
Otezla SupportPlus Specialists help your Medicare patients understand their current insurance plan and anticipated out-of-pocket costs for Otezla. For patients that want to switch Medicare plans, we can help identify other local options. We may also be able to refer eligible patients ‡ for Medicare Extra Help (Low Income Subsidy) or put them in touch with independent nonproﬁt foundations
‡Support provided through independent nonproﬁt foundations and not through Otezla SupportPlus. Otezla SupportPlus has no control over independent, third-party programs and provides referrals as a courtesy only.
OTEZLA NURSE PARTNER PROGRAM
The Otezla Nurse Partner § program works closely with your new Otezla patients to provide tailored support, including how to get started on Otezla, maintaining a treatment routine, and guiding them to resources based on their individual goals.
Enrollment is simple for your Otezla patients. Encourage them to sign up for Otezla SupportPlus to access the Otezla Nurse Partner program today!
§Otezla Nurse Partners are nurses by training, but they are not part of a patient’s treatment team or an extension of their doctor’s office. Patients will be referred to their doctor’s office for clinical advice.
WHETHER IT’S YOU, YOUR OFFICE, OR YOUR PATIENTS, GET ANSWERS
TO QUESTIONS BY CALLING OTEZLA SUPPORTPLUS AT
Otezla is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation
Warnings and Precautions
Hypersensitivity: Hypersensitivity reactions, including angioedema and anaphylaxis, have been reported during postmarketing surveillance. If signs or symptoms of serious hypersensitivity reactions occur, discontinue Otezla and institute appropriate therapy
Diarrhea, Nausea, and Vomiting: Cases of severe diarrhea, nausea, and vomiting were associated with the use of Otezla. Most events occurred within the first few weeks of treatment. In some cases, patients were hospitalized. Patients 65 years of age or older and patients taking medications that can lead to volume depletion or hypotension may be at a higher risk of complications from severe diarrhea, nausea, or vomiting. Monitor patients who are more susceptible to complications of diarrhea or vomiting; advise patients to contact their healthcare provider. Consider Otezla dose reduction or suspension if patients develop severe diarrhea, nausea, or vomiting
Depression: Carefully weigh the risks and benefits of treatment with Otezla for patients with a history of depression and/or suicidal thoughts/behavior, or in patients who develop such symptoms while on Otezla. Patients, caregivers, and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal thoughts or other mood changes, and they should contact their healthcare provider if such changes occur
Plaque Psoriasis: Treatment with Otezla is associated with an increase in depression. During clinical trials in patients with moderate to severe plaque psoriasis, 1.3% (12/920) of patients
reported depression compared to 0.4% (2/506) on placebo. Depression was reported as serious in 0.1% (1/1308) of patients exposed to Otezla, compared to none in placebo-treated patients (0/506). Suicidal behavior was
observed in 0.1% (1/1308) of patients on Otezla, compared to 0.2% (1/506) on placebo. One patient treated with Otezla attempted suicide; one patient on placebo committed suicide
Psoriatic Arthritis: Treatment with Otezla is associated with an increase in depression. During clinical trials, 1.0% (10/998) reported depression or depressed mood compared to 0.8%
(4/495) treated with placebo. Suicidal ideation and behavior was observed in 0.2% (3/1441) of patients on Otezla, compared to none in placebo-treated patients. Depression was reported as serious in 0.2% (3/1441) of
patients exposed to Otezla, compared to none in placebo-treated patients (0/495). Two patients who received placebo committed suicide compared to none on Otezla
Behçet’s Disease: Treatment with Otezla is associated with an increase in depression. During the clinical trial, 1% (1/104) reported depression or depressed mood compared to 1% (1/103)
treated with placebo. No instances of suicidal ideation or behavior were reported in patients treated with Otezla or treated with placebo
Weight Decrease: Monitor body weight regularly; evaluate unexplained or clinically significant weight loss, and consider discontinuation of Otezla
Plaque Psoriasis: Body weight loss of 5-10% occurred in 12% (96/784) of patients with moderate to severe plaque psoriasis treated with Otezla and in 5% (19/382) of patients treated with
placebo. Body weight loss of ≥10% occurred in 2% (16/784) of patients treated with Otezla compared to 1% (3/382) of patients treated with placebo
Psoriatic Arthritis: Body weight loss of 5-10% was reported in 10% (49/497) of patients taking Otezla and in 3.3% (16/495) of patients taking placebo
Behçet’s Disease: Body weight loss of >5% was reported in 4.9% (5/103) of patients taking Otezla and in 3.9% (4/102) of patients taking placebo
Drug Interactions: Apremilast exposure was decreased when Otezla was co-administered with rifampin, a strong CYP450 enzyme inducer; loss of Otezla efficacy may occur. Concomitant use of Otezla with CYP450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin) is not recommended
Plaque Psoriasis: The most common adverse reactions (≥5%) are diarrhea, nausea, upper respiratory tract infection, and headache, including tension headache. Overall, the safety profile of Otezla
in patients with mild to moderate plaque psoriasis was consistent with the safety profile previously established in adult patients with moderate to severe plaque psoriasis
Psoriatic Arthritis: The most common adverse reactions (≥5%) are diarrhea, nausea, and headache
Behçet’s Disease: The most common adverse reactions (≥10%) are diarrhea, nausea, headache, and upper respiratory tract infection
Use in Specific Populations
Otezla has not been studied in pregnant women. Advise pregnant women of the potential risk of fetal loss
Please click here for the full Prescribing Information.
Otezla® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.